SEROLOGICAL
TESTING
Single RDT* or laboratory-based immunoassay†
Report positive
Report negative
ASSESSMENT FOR TREATMENT
(using clinical criteria* and/or non-invasive tests (NITs) for presence of cirrhosis, i.e. APRI score‡ >2 or based on TE§)
(to further guide who to treat and not treat, if no evidence of cirrhosis)
>30 years (in particular)
≤30 years
Persistently abnormal
Intermittently abnormal
Persistently normal
>20,000 IU/mL
2000–20,000 IU/mL
<2000 IU/mL
• Tenofovir or entecavir
• Entecavir in children aged 2–11 years
MONITORING
• Ultrasound and serum AFP
• Adherence at each visit, if on treatment
• ALT, HBV DNA and HBeAg
• Staging of liver disease (clinical criteria and NITs (e.g. APRI in adults or TE))
• Renal function and risk factors for renal dysfunction
by Raj
